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THE RATE OF PLACENTA ACCRETA AND PREVIOUS EXPOSURE TO UTERINE 
SURGERY 
Anne Cooper MA, Lisbet Lundsberg PhD, Daniel Bercik, Jessica L. Illuzzi MD.  Department of 
Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, 
CT. 
 
Placenta accreta is a disorder of abnormal placentation that causes significant maternal morbidity and 
mortality, and whose incidence is rising in the US.  Accreta is thought to be linked closely to endometrial 
disruption introduced by exposure to uterine surgery; its connection to cesarean delivery is well-
established, however, there is a poorer understanding of the contribution made by other forms of uterine 
surgery, and by relatively subjective indications for which women with placenta accreta may have initially 
received a cesarean delivery.  The aims of the study were to quantify the rate of placenta accreta at YNHH, 
the rate of exposure to various uterine surgeries prior to the accreta pregnancy, and the rate of subjective 
indication for primary cesarean delivery amongst all patients with placenta accreta from 1995-2011. 
Among the 72,845 births during the study period, 249 cases of placenta accreta were identified via query of 
pathology records, including 122 focal accreta, 63 accreta vera, 23 increta and 14 percreta. 
Twenty-seven cases were excluded due to lost chart, multiple accreta in a single patient, and absence of 
baseline birth data for Jan 1995 - June 1996; a total of 100 cases of non-focal accreta were included in the 
final analysis.  Non-focal accreta is increasing over the study period; the rate was 1.4 cases per 1,000 births; 
it increased on average 12% per 3-year period over the course of the study (95% CI -1.6% to 28.5%).  
Among all births, women with placenta accreta and a prior index cesarean delivery increased significantly 
over the study period, with a mean increase of  21.9%  per 3-year period (95% CI1.4% to 46.6%), while 
those with placenta accreta and other index uterine surgery increased by 71.1% per 3-year period (95% CI 
10.4% to 165%).  Over this 15 year period, the cumulative increase in risk of having placenta accreta in the 
setting of prior cesarean delivery was 2.69 (95% CI 1.07 – 6.8) while the cumulative increase in risk for 
having placenta accreta in the setting of prior other uterine surgery was 14.66 (95% CI 1.64 – 131).  There 
was no significant difference in rate of placenta accreta with prior index cesarean delivery for subjective or 
objective indication.  Placenta accreta in the setting of prior uterine surgery is increasing over time.  Larger 
studies are needed to further elucidate the increasing role of prior uterine surgery on the development of 





Many thanks go to the many people who have contributed significantly through the course of this 
project.  Brian West, MD, Director of Anatomic Pathology at Yale-New Haven Hospital, has 
been a tireless, insightful, enthusiastic partner in exploring the vagaries of pathologic diagnosis of 
placenta accreta, along with Linda Hager, his very capable and pleasant assistant.  The planning 
and feedback for the project was so enriched by the engagement, patience and creativity of Divya 
Patel, PhD and other members of the Comparative Effectiveness Working Group.  Daniel Bercik, 
research assistant, and his advisor Chris Pettker, MD provided deeply valued feedback and 
assistance in data collection and discussion of the project.  Lisbet Lundsberg has provided 
wonderful feedback and a keen eye throughout the project, as well as being delightful to work 
with.  Most of all, Dr. Jessica Illuzzi’s vision, dedication to positively shaping the field of 
obstetrics & gynecology through incisive research, guidance and friendship has been a highlight 
and a privilege.  
 
 
Table of Contents 
Abstract ............................................................................................................................................ 2 
Acknowledgements .......................................................................................................................... 3 
Table of Contents ............................................................................................................................. 4 
Introduction ...................................................................................................................................... 5 
Overview ...................................................................................................................................... 5 
Incidence ...................................................................................................................................... 6 
Pathogenesis ................................................................................................................................. 6 
Risk Factors ................................................................................................................................. 9 
Diagnosis ................................................................................................................................... 11 
Diagnostic imaging ................................................................................................................ 11 
Clinical Diagnosis .................................................................................................................. 12 
Histopathological Diagnosis .................................................................................................. 13 
Comparison of modes of diagnosis ........................................................................................ 14 
Variation in diagnostic criteria across accreta research studies ............................................. 15 
Outcomes of Placenta Accreta ................................................................................................... 16 
Public Health Impact .............................................................................................................. 17 
Management ............................................................................................................................... 17 
Prevention?  A closer look at uterine surgery ............................................................................ 18 
Reasons for increasing rate of cesarean delivery ................................................................... 19 
Summary .................................................................................................................................... 21 
Patient characteristics ................................................................................................................. 32 
Comparison between focal and non-focal accreta ................................................................. 32 
Comparison between accreta vera, increta and percreta ........................................................ 33 
Description of accreta trends, with focal accreta included ........................................................ 34 
Exposure to uterine surgery among non-focal accreta cases ..................................................... 38 
Trend in non-focal accreta rate .................................................................................................. 39 
Association between exposure to index uterine surgery and risk of non-focal accreta ............. 41 
Characteristics of women with no prior uterine surgery ............................................................ 46 
Discussion ...................................................................................................................................... 48 






Placenta accreta is a disorder of abnormal placentation that causes significant maternal 
morbidity and mortality, and whose incidence is rising in the US.(1,2,3,4)  In placenta 
accreta, placental villi invade beyond their usual implantation in the decidua basalis into 
or through the myometrium. This impairs a major physiologic mechanism to control 
postpartum bleeding, leading to high rates of hemorrhage and increased maternal and 
perinatal morbidity and mortality.  Women with placenta accreta face a range of 
complications, including acute respiratory distress syndrome, disseminated coagulation, 
transfusion-related complications, injury to ureters, bladder or bowel, emergency 
hysterectomy and death.(1)  In the setting of severe hemorrhage, hysterectomy may be 
necessary as a lifesaving intervention; despite aggressive surgical intervention, maternal 
death rates in placenta accreta have been reported as high as 7%.(5) 
The incidence of placenta accreta has risen significantly compared with rates in the 
1950s,(6) recent estimates place it at 1 per 533 deliveries to 1 per 2510 deliveries.(6,7)  
Cesarean delivery has been identified as a significant factor leading to the increase in 
accreta rates, attributed to uterine wall disruption and resulting uterine scar.(6,7,8,9,10)  
Other types of uterine instrumentation that disrupt the endometrium are also viewed as 
potential contributors, though their role is less clearly defined(1,10,11,12)  As patterns of 
cesarean delivery and other uterine surgery change, it is important to examine their 
potential contribution to the rate of placenta accreta.(3)  In the United States, the cesarean 




As rates of cesarean delivery increase, a recent study at one tertiary care center showed 
that the majority of indications for primary cesarean from 2003-2009 were done for 
indications that can be considered subject to varied interpretation by different clinicians.  
These more subjective indications include non-reassuring fetal heart tracing, labor arrest 
disorders and suspected macrosomia.(13)  Elective cesarean per maternal request can also 
be considered subjective, or without objective medical indication.  Over time, the use of 
other uterine procedures, including myomectomy, has also shifted.  To date, there has not 
been an effort to examine the rate of exposure to previous uterine surgery among patients 
with placenta accreta, in order to better understand the indications that may underlie the 
increasing rates of placenta accreta. 
Incidence 
Rates of placenta accreta are estimated to have increased significantly compared with 
rates in the 1950s.(6)  Recent estimates place the incidence at 1 per 533 deliveries to 1 
per 2510 deliveries,(6,7,14) in comparison with rates from the 1930s-1950s of 1:30,000 
births.(15)  Estimates of the incidence of placenta accreta vary widely, due to variations 
in diagnostic criteria and study population; nevertheless, there is consistent demonstration 
in the literature that the rate has increased substantially over time.   
Pathogenesis 
The placenta is a remarkable organ, constantly undergoing change throughout its 
relatively brief existence.  Upon implantation of an embryo, the endometrium becomes 
known as the decidua, and forms the maternal portion of the placenta.  The decidua 
develops into several layers: the decidua compactus is the most superficial to the uterine 
cavity.  Beneath it is the stratum spongiosum, below this is the stratum compactum or 
dedicua basalis.(16,17)  This barrier layer interacts with invading trophoblastic cells, and 
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lies adjacent to the underlying myometrium, with an intervening fibrinoid layer known as 
Nitabuch’s layer.(18)  At parturition, the decidua sloughs off at the decidua basalis, and 
the maternal spiral arteries that penetrate the decidua at right angles to fill the intervillous 
space are compressed by uterine contraction and spasm to achieve hemostasis. 
Placenta accreta is a relative newcomer to obstetric pathology.  It was first documented in 
1937 by Irving & Hertig, who described it as “the abnormal adherence, either in whole or 
in part, of the afterbirth to the underlying uterine wall,” which they attributed to a 
deficiency or absence of the decidua basalis.(19)  There are three types of placenta 
accreta: placenta accreta vera (more often termed just placenta accreta) denotes 
placental attachment directly onto the myometrium without intervening decidua basalis, 
increta indicates invasion into the myometrium, percreta denotes penetration through the 
myometrium into or beyond the serosa, which may include involvement of nearby 
organs, including bladder or bowel.(Fig. 1)  The term placenta accreta can be used as an 




Fig. 1.  Types of placenta accreta by degree of invasion. 
Placenta accreta can also be categorized according to the surface area of the placenta that 
is abnormally adherent, as focal, partial or total.(16) The designation of focal accreta is 
useful to denote a small area of abnormal placentation, as small as one cotyledon.(20,21), 
however the clinical significance of this finding is less clear.  
The key pathologic finding associated with placenta accreta is the absence or deficiency 
of the decidual plate, with the finding of placental villi embedded directly onto 
myometrium, often described in histopathology as the presence of basal plate myometrial 
fibers.(16)  More recently, accreta has also been found to include abnormally invasive 
extravillous trophoblast, underlining the importance of the balance between decidua and 
trophoblastic invasion.(22) Uterine surgery or procedures that disrupt the endometrium 
are assumed to increase risk of accreta through their potential disruption of 
decidualization, and possible creation of scar tissue.(21)  There are several, likely 
overlapping, theories advanced to explain the etiology of placenta accreta.  The first 
Increta 








theory is that a deficiency or absence of decidua prevents its usual role in preventing 
excessive trophoblast invasion into the myometrium.(23,24) There is also evidence that 
deficient vascularization and resulting negative oxygen tension in scarred areas of the 
uterus leads trophoblastic cells to invade more deeply to establish adequate blood 
supply.(5) Finally, the oldest theory posits that trophoblastic tissue itself is abnormally 
invasive.(16,26)    The fact that placenta accreta was first recognized less than 100 years 
ago suggests a significant iatrogenic component.(27)  
Risk Factors 
Although the etiology of placenta accreta is still a topic of debate, the risk factors for 
placenta accreta are better understood.  According to one study, approximately 95% of 
women diagnosed with placenta accreta have identifiable risk factors.(10)  The most 
common presentation of placenta accreta is a woman with one or more previous cesarean 
deliveries and current placenta previa.  There is robust evidence that the risk of placenta 
accreta also increases significantly with repeated cesarean deliveries.(29,31,32,33)  A 
prospective observational cohort study of 30,132 women with cesarean delivery without 
labor taking place in four academic centers between 1999-2002 scrutinized number of 
placenta accreta by number of previous cesarean deliveries.  The study identified cases of 
accreta via histopathology, or via clinical diagnosis in cases where hysterectomy was not 
performed.  Specific criteria for clinical diagnosis were not enumerated.  They found that 
risk of accreta in women with placenta previa rises from 3% in the setting of one 
previous cesarean delivery, to 11%, 40%, 61% and 67% with two, three, four and five or 
more previous cesarean deliveries, respectively, a trend that is mirrored at a lower rate in 
patients without placenta previa, as well.(8)  Compared with a first vaginal birth, women 
with a first birth by cesarean have 1.9 times higher odds (CI 1.3-2.8) of placenta accreta 
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in the subsequent pregnancy.(12)    Having two or more cesarean deliveries is associated 
with an odds ratio of 8.6 (95% CI 3.54-21.08) for development of placenta accreta in the 
subsequent pregnancy.(7)  In view of the strength of this association, the increasing rate 
of cesarean delivery is agreed to be one of the most significant factors contributing to 
placenta accreta.(8,9,11)   
Placenta previa is also independently associated with placenta accreta, particularly when 
the placenta is overlying a previous uterine scar.  Abnormal placentation is often found in 
association with placenta previa. Accreta is now seen in 9.3% of women with placenta 
previa.(7)  Other risk factors include advanced maternal age, multiparity, Asherman 
syndrome, leiomyomata, radiation exposure, uterine anomalies, hypertension and 
smoking.(1,6,7,11,29,30) 
Given their disruption of the endometrium, it is likely that other forms of uterine surgery, 
such as myomectomy, endometrial ablation, septum resection, and lysis of adhesions also 
contribute to risk of placenta accreta; however, comparably little has been done to 
investigate this association, aside from case reports.(34,35)  Fibroids contribute to 
infertility, and prevalence in the United States may be as high as 13% however, no direct 
causal relationship between fibroids and infertility has been established.(36)  Treatment is 
tailored to the reproductive wishes of the patient, and treatment regimens are shifting 
over time, including an effort to study medical therapies; however, myomectomy, 
endometrial ablation and other surgical interventions are also still frequently used,(37) 
with ongoing debate as to the effectiveness of abdominal versus laparoscopic or robotic 
approaches for myomectomy.(38)  There is relatively little data available as to rate of 





There are three modes of diagnosis for placenta accreta:  pre-natal imaging, intrapartum 
clinical findings, and histopathology from a placental or uterine specimen.  A fourth 
mode of diagnosis is in development: immunohistochemical markers that could help 
predict presence and/or severity of placenta accreta. (1,21)    
Prenatal diagnosis of placenta accreta mainly takes place via ultrasound, usually during 
the second or third trimester.  Criteria for sonographic diagnosis of placenta accreta 
include a range of associated findings, including loss of the normal hypoechoic 
retroplacental zone; presence of multiple vascular lacunae within the placenta; blood 
vessels or placenta bridging the uterine-placental margin, myometrial-bladder interface or 
crossing the uterine serosa; retroplacental myometrial thickness of <1mm; and presence 
of numerous coherent vessels visualized with 3-dimensional power Doppler in basal 
view.(1)  Across four studies, sonographic diagnosis of placenta accreta has been 
associated with a sensitivity of 77.0 – 93.0% and specificity of 71.0 – 96.8%, with a PPV 
of 65.0 – 87.5% and NPV of 92.0 – 98.0%.(40,41,42,43)  Ultrasound is particularly 
useful for ruling out accreta, given its high negative predictive value.(40)  In women with 
low-lying placenta or placenta previa in setting of previous uterine instrumentation, it is 
particularly important to be vigilant in screening for placenta accreta.   
MRI can also be used in evaluation of placenta accreta, though evidence on its utility is 
mixed.  It may be particularly useful in cases of posterior placenta(44) or where patient 
habitus limits sonography and also has the advantage that it is not operator dependent.  
An analysis in 2007 showed that three MRI findings were associated with abnormal 
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placentation: abnormal uterine bulging, heterogenous signal intensity, and presence of 
dark intraplacental bands on T2-weighted images.(45)  One study evaluated ultrasound 
and MRI diagnosis of placenta accreta in a cohort of 453 women with placenta previa, 
previous cesarean delivery and low-lying anterior placenta, or previous myomectomy; it 
found ultrasound to accurately predict placenta accreta in 30 of 39 women and 
appropriately rule out accreta in 398 of 414 women (sensitivity 77%, specificity 
96%).(42)  In the same study, among 42 cases with inconclusive or suspicious findings 
on ultrasound, MRI was a useful adjunct: it accurately predicted placenta accreta in 23 of 
26 cases, and correctly ruled out placenta accreta in 14 cases (sensitivity 88%, specificity 
100%).(42)  Given its increased expense and comparable sensitivity and specificity to 
ultrasound, MRI is perhaps most often useful as a second stage of evaluation in cases 
where ultrasound findings are inconclusive.  
The extent of myometrial invasion noted on ultrasound reflects the type of accreta, 
particularly denoted by presence of blood vessels or placenta traversing the myometrium 
or crossing the serosa.  Lower degrees of invasion are more difficult to appreciate, and 
there is no data on diagnosis of focal accreta via ultrasound or MRI, though positive 
identification would likely be limited to cases with invasion that disrupts macroscopic 
architecture.  
Clinical Diagnosis 
The second mode of diagnosis is intrapartum clinical diagnosis, based on presence of 
hemorrhage or retained placenta without a clear plane of separation.  In cases of clinical 
suspicion, submission of the placenta for pathologic evaluation is warranted.  A 2006 
study by Silver and colleagues, which established accreta risk relative to number of 
13 
 
previous cesarean, used both pathologic diagnosis in cases where hysterectomy was 
performed, and clinical findings of adherent placenta with difficult removal, in cases 
where hysterectomy was not performed.(8)  The authors recognize that a possible 
limitation of the study was the use of a clinical definition for accreta; however, for their 
study, histologic diagnosis was only available when hysterectomy was performed.  An 
alternative reason for inclusion of clinical diagnostic criteria is among populations where 
access to sonography is limited.(32)   
Several other studies have used a mix of clinical and pathologic criteria.  For instance, 
Gielchinsky et al 2002 used the definition below, which was subsequently replicated in 
another study: (28)  
(1) Difficult manual, piecemeal removal of the placenta, that was 
performed if no evidence of placental separation was noticed at least 20 
min after parturition, and despite of active management of the third stage 
of labour (i.e. administration of intravenous oxytocin, transabdominal 
manual massage of the uterus, drainage of blood from the placenta, and 
firm-controlled traction of the umbilical cord); OR 
(2) sonographic evidence of retained placental fragments requiring 
curettage after vaginal delivery; OR 
(3) heavy bleeding from implantation site after removing the placenta 
during conservatively managed caesarean section, with excision of part of 
the uterine wall and the attached placenta, or over-sewing the bleeding 
defects; OR 
(4) histologic confirmation of a hysterectomy specimen.(29) 
 
Histopathological Diagnosis 
The third mode of diagnosis is via histopathology, which relies on demonstrating the 
presence of basal plate myometrial fibers, or direct apposition of trophoblastic tissue onto 
the underlying myometrium, without intervening decidual tissue.(16)  The diagnosis can 
be made on hysterectomy specimen, but also on placenta or placenta with uterine biopsy, 
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if myometrial fibers are found to be present either immediately adjacent to placental villi 
or with only an intervening fibrin layer.(18,20) 
Comparison of modes of diagnosis 
There are pros and cons of the three diagnostic modalities for accreta: they have different 
functions and operate at different times during the pregnancy and peripartum periods. 
Their varying use in previous research makes comparison across studies difficult.  
Prenatal diagnosis via ultrasound usually occurs during the second and third trimesters, 
though it has been documented in the first trimester. Antenatal diagnosis provides the 
opportunity for delivery planning, which is an important way to reduce intrapartum 
hemorrhage and improve outcomes.  Intrapartum clinical diagnosis is made within the 
acute management setting, where the diagnosis of accreta is secondary to effective 
assessment of the evolving problem and adept management.  Clinical severity is also the 
major factor used in evaluating the impact of placenta accreta, and can be important in 
distinguishing between symptomatic non-focal accreta and asymptomatic cases of focal 
accreta.  (20,21)             
Finally, postpartum pathologic diagnosis occurs on either placental or hysterectomy 
specimen and provides the most objective basis for diagnosis; however, it is also subject 
to uncertainty, particularly in relation to focal placenta accreta.  Focal placenta accreta is 
often less clinically severe,  and may even be clinically silent, making its  relevance 
unclear.   In contrast, some argue that any case of retained placenta or manual removal of 
placenta represents a minor case of abnormally adherent placenta.(16,21,47)  One study 
compared placentas with basal plate myometrial fibers on histopathology but no clinical 
findings of accreta (so-called ‘occult placenta accreta’) with placentas from similar 
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deliveries without basal plate myometrial fibers.(48)  They found that the occult placenta 
accreta cases had a significantly higher level of extravillous trophoblast, signaling that 
although they were not symptomatic, they had evidence of the same pathology 
underlying overt placenta accreta.(25)  Thus, on one hand some argue that focal placenta 
accreta is not relevant because it often does not have clinical findings of placenta accreta; 
alternatively, if there is a shared pathology, it may help advance our understanding of 
accreta. 
Variation in diagnostic criteria across accreta research studies 
One of the reasons for varying estimates of incidence of placenta accreta is that studies 
have used differing diagnostic criteria over time, with a contrast between those that rely 
strictly on histopathologic diagnosis, usually from hysterectomy specimen, and those that 
accept both clinical and pathologic evidence.   
The degree of overlap between clinical suspicion and pathologic diagnosis can be 
problematic.  In one retrospective review of cases of accreta between 1985 and 1994, 
clinical suspicion of placenta accreta was found to correctly identify only 48% of cases.  
The remaining 62 of 127 hysterectomy cases with operative diagnosis of accreta were 
found on pathology to not meet criteria for placenta accreta.(6)  One solution to this has 
been to rely on only on pathological diagnosis rather than using clinical criteria; in many 
cases, only hysterectomy specimens have been examined, although placenta accreta can 
be diagnosed on placental specimens, as well.(49) 
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Outcomes of Placenta Accreta 
Developing an accurate understanding of the prevalence, risk factors, and options for 
prevention and management of placenta accreta is of the utmost importance, given its 
particular impact on maternal health.   
Women with placenta accreta face a range of sequelae, including not only hemorrhage, 
but also blood transfusion with associated complications, injury to local organs, amniotic 
fluid embolism, postoperative infection, thromboembolism, multi-organ failure and 
death.(1)  One case series of 76 patients with accreta found that blood transfusion was 
required in 80% of deliveries, and that 40% of cases required transfusion of 4 units or 
more of packed red blood cells.(10)  Average blood loss at time of delivery can be 3000-
5000mL, and may exceed 10L.(50,51)   
In the setting of severe hemorrhage, hysterectomy may be necessary to prevent maternal 
death.  Placenta accreta is now the leading cause of peripartum hysterectomy in the 
developed world.(2,52)  One retrospective cohort study of all deliveries occurring in three 
hospitals in Dublin, Ireland from 1966-2005 found that the rate of peripartum 
hysterectomy due to placenta accreta increased from 5.4% during 1966-1975, to 46.5% 
from 1996-2005, an increase of more than 700%, representing a major shift in the profile 
of indications for peripartum hysterectomy.(52)  Even with aggressive surgical 
intervention, maternal death rates in placenta accreta have been reported as high as 
7%.(5)  Placenta accreta also poses a threat to the infant, mostly due to preterm birth due 
to vaginal bleeding or electively to avoid hemorrhage.  A survey of 109 cases of placenta 
percreta occurring among patients of members of the Society of Perinatal Obstetricians 
over a three-year period found a perinatal mortality  rate of 9%.(5)  
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Public Health Impact 
The impact of placenta accreta on public health is also significant.  A recent decision 
analysis sought to forecast the effect of rising primary cesarean section rates on annual 
incidence of previa and accreta.  The study reported that if primary and repeat cesarean 
rates continue their recent rate of rise, by 2020 the cesarean delivery rate will be 56.2%, 
and there will be an additional 6,236 previas, 4,504 accreta, and 130 maternal deaths 
annually.(4)  Of interest, the study also found that the rise in rates of placenta accreta 
trails the rise in cesarean rate by an estimated six years.  The findings were consistent 
with another model predicting that for every 5% increase in the elective primary CS rate, 
will come up to 32 more maternal deaths, 24,000 more surgical complications, and 
between $750 million and $1.7 billion in healthcare expenditures.(53) 
This concerning data must be considered in light of recent deterioration of maternal 
mortality in the United States.  From 1998 to 2004, maternal mortality rate in the United 
States rose from 10 per 100,000 to 14 per 100,000 live births.(50)  Although the reason 
for this rise is unclear, the increase in rates of placenta accreta is thought to make a 
significant contribution.(6,7,9,40)  
Management 
It is important to consider both prevention and management so as to minimize the impact 
of rising rates of placenta accreta.  Optimizing management is receiving a great deal of 
attention in the literature.  Broad themes include the importance of prenatal diagnosis to 
facilitate delivery planning and the crucial role of multidisciplinary care teams.  Given 
the likelihood of massive hemorrhage and need for cesarean hysterectomy, and 
possibility of other complications, pre-delivery planning is essential in cases of suspected 
placenta accreta.  Scheduled cesarean delivery with a multidisciplinary team and 
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measures in place to anticipate possible accreta has been associated with reduced 
morbidity, reduced blood loss, and improved outcomes.(1,10,40)   
Prevention?  A closer look at uterine surgery 
Despite our best efforts to optimize management, it is also crucial to focus attention on 
ways to avert placenta accreta.  With the strong association between previous cesarean 
delivery and placenta accreta, and the significant increase in cesarean delivery rates over 
the past several decades, cesarean delivery rates are an important target.  Modern 
cesearean delivery came about in 1926 with the advent of a new surgical approach; this, 
coupled with improved use of uterotonics, aseptic technique, and other advances led to 
far improved survival rates after cesarean.  The rate of cesarean delivery in the US rose 
from 5% in 1970 to 25% in 1989 to 32.9% in 2009, or an increase of over 600%.(3)  The 
rate of vaginal birth after previous cesarean delivery (VBAC) has decreased significantly.  
As the VBAC rate declines, for every woman who has a primary cesarean delivery, her 
likelihood of having a subsequent cesarean delivery increases, and of developing placenta 
accreta.   
Cesarean delivery is the most common surgical procedure undergone by women in the 
United States.  The National Center for Health Statistics estimated that 15% of inpatient 
surgeries that took place in the United States in 2001 were cesarean deliveries, or 
approximately one million of a total of seven million surgeries.(53)  This estimate 
underscores the significant implications that cesarean delivery rates have for healthcare 
utilization more broadly. 
Although cesarean delivery is ubiquitous, it is important to be cognizant of both the 
short- and long-term complications.  The risk of complications increases with multiple 
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cesareans.  One study found that women with three or more planned cesarean deliveries 
had significantly higher incidence of excessive blood loss (7.9% versus 3.3%; P <.005), 
difficult delivery of the neonate (5.1% versus 0.2%; P < .001), and dense adhesions 
(46.1% versus 25.6%; P <.001) compared with a group after second cesarean.(50)  They 
also reported that risk of major complication (uterine rupture, hysterectomy, re-
laparotomy, bladder or bowel injury, thromboembolism, or excessive blood loss) was 
also significantly higher in the repeat cesarean group(8.7% versus 4.3%, P = .013), and 
increased with the delivery index number: 4.3%,7.5%, and 12.5% for second, third, and 
fourth or more cesarean delivery, respectively (P for trend = .004).(55)   
Reasons for increasing rate of cesarean delivery 
The reasons for the increase in cesarean rate continue to be a subject of debate.  Possible 
explanations include increased maternal age, worse maternal health, increased rates of 
obesity, maternal preference, provider convenience, and avoidance of legal liability.  
With regard to age, Northern Europe has had a similar demographic shift toward 
increased maternal age at childbirth without such an increase in cesarean rate.(53)  Also, 
within the United States cesarean delivery rates have increased across all age groups.(53)  
Alternative explanations include patient and provider preference/convenience, avoidance 
of legal liability, and malpractice awards; for a small portion of cesarean deliveries, they 
may be attributed to a decrease in clinical skills for and change in attitudes toward 
operative delivery.(2,3,4,13)  
It is certainly the case that there is a crucial role for cesarean delivery.  In West Africa, 
for example, there is a threshold relationship between the maternal mortality ratio and 
cesarean rate: countries or regions with maternal mortality ratios above 450 per 100,000 
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typically exhibit CD rates below 1%.(56)  The World Health Organization set a target 
rate for cesarean delivery of 15%, estimating that 12-15% of deliveries will have a 
condition needing intervention, including cesarean.(56)  On the opposite end of the 
spectrum, the WHO points out that cesarean rates above 15% are accompanied by 
increased risk to both mother and baby.  Indeed, while cesarean rates in the United States 
have increased over recent decades, maternal and neonatal outcomes have not 
improved.(13)  
In light of concern over high cesarean rates, a few recent studies have sought to elucidate 
the clinical situations and indications that precipitate cesarean delivery, including those 
marked by variability in clinical thresholds to intervene by cesarean delivery.  A recent 
study investigated the indications for primary cesarean delivery at Yale-New Haven 
Hospital over a seven year period, 2003-2009.(13) They found that the rate of cesarean 
delivery increased from 26.0% to 36.5% over that time, equivalent to an increase of 73%; 
the rate of repeat cesarean also increased, from 9.8% in 2003 to 14.8% in 2009.  The 
VBAC rate during the study period dropped from 17.8% to 7.8%.  The study reported 
that 68% of the increase in primary cesarean rate could be attributed to more subjective 
indications, including non-reassuring fetal heart tracing (32%), labor arrest disorders 
(including arrest of dilation and arrest of descent; 18%), suspected macrosomia (10%) 
and elective per maternal request (8%).(See Fig 2; 13) The study also reported that rates 
of cesarean delivery for multiple gestation and preeclampsia increased at rates 200% and 
87% higher, respectively, than would be predicted based on population increases in 
multiple gestation and preeclampsia.(11)    
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Of note, Although rates of cesarean for non-reassuring fetal heart rate have increased 
over time, neonatal outcomes have not improved.(52)  Several recent studies have 
suggested that exercising increased patience in the setting of active phase arrest of labor 
could lead to successful vaginal delivery in 33 to 61% of cases.(53)  
 
Fig. 2.  Indication for primary cesarean deliveries at Yale-New Haven Hospital, 
2003-2009.  Adapted from Barber et al 2011.(13)  
 
Summary 
Placenta accreta is a growing threat to maternal health, due at least in part to rising rates 
of cesarean delivery, with contributions from other uterine surgeries as well.  As 
antenatal diagnosis and peripartum management improve, secondary prevention of poor 
outcomes among women with placenta accreta is more effective.  Better provider 
preparation and provision of multi-disciplinary peripartum care have been shown to 
improve outcomes, but will not help turn the tide of this growing problem.  It is important 
to seek better understanding of potential modifiable risk factors that may aid in primary 
prevention.  Among these, recent evidence that a majority of primary cesarean deliveries 
at one tertiary care center occurred due to a subjective indication suggests that a 
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proportion of these interventions could have been averted without compromising 
maternal or fetal health, thereby reducing the number of women who cross that threshold 
of increased risk for subsequent accreta.  Rates of myomectomy and other surgical 
fertility-enhancing management of fibroids have also changed over time.  Building a 
clearer picture of the rates of and indications for previous uterine surgery may help us not 




Statement of purpose, specific hypothesis, and 
specific aims of the thesis 
Because placenta accreta is associated with significant maternal and perinatal morbidity 
and mortality, it is important to establish the rate of placenta accreta, and profile the risk 
factors contributing to placenta accreta over time.  To date, there are no documented 
efforts to examine the indications for index uterine surgery in women with placenta 
accreta.   
In this study, we will retrospectively determine the rate of placenta accreta at Yale-New 
Haven Hospital from 1996 to 2011 and the indications for index uterine surgery in these 
patients, in order to meet three aims: 
Aim 1: To determine the rate of placenta accreta at Yale-New Haven Hospital over the 
period of 1996 to 2011. 
Aim2:  To determine the rate of previous uterine surgery exposure among patients with 
placenta accreta.   
Aim 3: To determine the rate of index cesarean deliveries due to subjective indications in 
patients with placenta accreta.  
Analysis will include a retrospective examination of indication for primary uterine 
surgery by year of accreta diagnosis, including calculating change in rates of placenta 
accreta associated with a given indication over time, based on number of all births at 
YNHH in a given year.  We will also analyze indication for index uterine surgery, and 
plan to calculate proportion of uterine surgeries due to each indication, to compare for 
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change in proportion over time.  Finally, the analysis will include presence of other risk 
factors, including number of cesarean deliveries or other uterine surgeries, maternal age, 
and comparison of outcomes by risk exposure.  Results from this study will inform a 
future extension of the project, to incorporate a control group for comparison.   
Establishing whether the rate of placenta accreta is increasing at Yale-New Haven 
Hospital, whether the profile of patient outcomes has shifted over time, and gaining a 
better understanding of the indications for which women are receiving first exposure to 
uterine surgery will demonstrate the degree to which cesarean section versus other uterine 
surgery is the index exposure in this group of patients with placenta accretaAmong 
cesarean deliveries, documenting the rate of more subjective indications and the change 
in this rate over time may provide evidence that at least a proportion of placenta accreta 
have the potential to be safely averted.  It may also help emphasize the need for further 
research on management of more subjective indications for cesarean delivery, including 
non-reassuring fetal heart tracing, suspected macrosomia, and labor arrest disorders, to 
optimize both maternal and neonatal outcomes.   
We hypothesize that rate of placenta accreta has increased over the study duration, and 
that a majority of patients will have previous uterine surgery exposure.  Of those with 
previous uterine surgery exposure, we anticipate that a significant proportion will have 
received their index exposure to cesarean delivery for subjective indications, including 





The group of patients with histopathologic diagnosis of placenta accreta at Yale-New 
Haven Hospital from January 1995 to December 2011 was generated via query of the 
database maintained by the Department of Surgical Pathology.  Query of all pathology 
reports that include text of ‘accreta’, ‘acreta’, ‘percreta’ or ‘increta’ from January 1995 to 
December 2011 returned a total of 249 cases with a diagnosis of abnormal placentation.   
Data on all births at Yale-New Haven Hospital were available for July 1996 through 
December 2011, based on obstetric department records kept monthly by an obstetric 
department nurse administrator.  This data formed the basis for analysis in the recent 
investigation of indication for cesarean delivery at Yale-New Haven Hospital,(13) 
improving our ability to compare findings between these two studies.  Hence, we decided 
to exclude cases of accreta occurring between January 1995 and June 1996 (n=22) from 
analysis of accreta trends, rather than augment with a different source of data for baseline 
birth rate.   
For purposes of evaluating diagnostic consistency, cases of placenta accreta were also 
identified via query of International Classification of Disease-9 (ICD-9) codes from 
hospital billing records.  ICD-9 codes 666.0 or 667.0 designate retained placenta with and 
without hemorrhage, including primary or secondary diagnosis of placenta accreta with 
and without hemorrhage.  This query generated a list of 802 cases from n October 1995 
(earliest available date) to December 2011.  
Comparison of the pathology-confirmed and ICD-9-based patient pools to examine 
diagnostic methods revealed significant discrepancy.  Of the 249 cases of placenta 
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accreta diagnosed by histopathology, which is often taken to be  the gold standard for 
diagnosis of placenta accreta, 173 (69.5%) were not captured in the ICD-9 code query.  A 
sample of cases from the ICD-9 query (20 randomly selected, 20 selected for clinical 
features consistent with placenta accreta) were reviewed for pathology findings, and did 
not return any additional cases of pathology-confirmed placenta accreta.  In addition, 
review of 82 randomly selected cases of the ICD-9 query revealed 17 cases (20.7%) that 
were consistent with placenta accreta by pathology.  There were numerous cases of mild 
retained placenta as well as normal deliveries that lacked a clear indication for their 
coding.  This data translates to a sensitivity of 31% and specificity of 99% for the 
identification of cases of placenta accreta by ICD-9 code compared with actual cases 
identified by histopathology (positive predictive value 9% and negative predictive value 
99%).  In this sample, with a prevalence of placenta accreta of 0.34%, the high specificity 
and high negative predictive value are essentially meaningless, and the low sensitivity 
and low positive predictive value reflect the inadequacy of using ICD-9 code to capture 
cases of placenta accreta.  These findings demonstrated that at our institution, ICD-9 code 
query cannot be relied upon to return all cases of placenta accreta; therefore clinical 
diagnosis through ICD9 code query was excluded as a means to establish this group of 
patients.  Thus, in this study we opted to restrict case inclusion to confirmed 
histopathologic diagnosis.  A total of 100 cases of non-focal accreta were included in the 






Fig. 3.  Cases of placenta accreta diagnosed by pathology at Yale-New Haven 
Hospital, 1995-2011.   
Of the 249 cases of placenta accreta diagnosed via histopathology, cases were divided 
between focal accreta, accreta vera, increta and percreta.(Fig. 3)  In this paper, placenta 
accreta will be used as the general term for all types of placenta accreta, while the 
specific type of abnormal placentation will be designated focal placenta accreta, placenta 
accreta vera, increta or percreta; the latter three types will collectively be referred to as 
non-focal accreta.  Two cases were excluded from the analysis because the patient chart 
had been lost.  There were three patients who each had two cases of diagnosed accreta.  
For these patients, the second instance of accreta was included in study analysis, and first 
was excluded.  Of the 244 remaining patients with placenta accreta, 22 cases that 
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occurred from January 1995 through June 1996 were excluded from analysis because 
birth data was not available for that time period.  A total of 122 cases of focal placenta 
accreta and 100 cases of non-focal accreta were used in the current analysis.  Non-focal 
accreta cases consisted of: 63 cases of placenta accreta vera, 23 cases of placenta increta 
and 14 cases of placenta percreta.  The 122 cases of focal placenta accreta were analyzed 
separately for patient characteristics and outcomes, because of varying sensitivity in 
diagnosis of focal accreta.  The Yale University Human Investigations Committee 
approved this protocol.    
Each patient chart was reviewed to determine obstetric history, indication for all previous 
cesarean deliveries, and maternal and perinatal care and outcomes for the accreta 
pregnancy.  All index cesarean deliveries were categorized as one of the following 
indications, based on the classification used by Barber et al: non-reassuring fetal heart 
tracing; labor arrest disorders (arrest of dilation or descent, including failed vacuum or 
failed forceps); suspected macrosomia; elective per maternal request; malpresentation; 
multiple gestation; preeclampsia, ecclampsia (including eclampsia and HELLP cases);  
other maternal or fetal indications; and other obstetric indications.(13)  Suspected 
macrosomia was defined by the provider based on either an ultrasound-derived estimated 
fetal weight or a clinical estimated fetal weight.  General practice has been a threshold of 
5,000g in non-diabetic patients, and 4,500g in diabetic patients.  Elective indication was 
defined as elective per maternal request, in absence of medical indication.  
Malpresentation represents breech presentation, face presentation, transverse lie, and 
unstable lie.  Preeclampsia, eclampsia, and hemolysis, elevated liver enzymes, and low 
platelets syndrome are represented in a distinct category because of their higher 
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frequency.  Other maternal indications are defined as other maternal conditions predating 
the pregnancy that could complicate delivery (e.g., maternal malignancy, maternal human 
immunodeficiency virus). Fetal indications include antenatal problems preceding the 
intrapartum period (e.g., fetal anomalies and intrauterine growth restriction). Other 
obstetric indications include conditions brought about by the presence of the current 
intrauterine pregnancy (e.g., placental abruption, accreta, previa, and cord prolapse). 
Indications designated as ‘subjective’ included: non-reassuring fetal heart tracing, labor 
arrest disorders, suspected macrosomia and elective by maternal request.  There were five 
patients for whom the indication for index cesarean delivery was unavailable.   In cases 
where more than one indication for cesarean delivery was present, the indication that 
most directly caused the plan of care to shift to cesarean delivery was used.   
Based on convention at YNHH, pregnancies recorded in the patient chart as ‘TAB’ were 
assumed to have a dilation & curettage (D&C) unless otherwise specified.  All dilation & 
curettage procedures were counted as part of the total number of uterine surgeries, with 
the exception of a curettage done as part of a more extensive uterine surgery, in which 
case it was accounted for as part of that surgery.  In several cases, the type of abortion in 
a patient’s obstetric history was not specified.  Such cases are included in the total 
number of abortions, but not categorized as spontaneous or induced.  For pregnancy 
terminations recorded as occurring during the first trimester, the gestational age was 
recorded as 12 weeks.  ‘Full term’ pregnancies were recorded as occurring at a 
gestational age of 40 weeks. 
For the 16 patients (focal accreta, n=12; accreta, n= 4) whose estimated blood loss during 
the accreta delivery was listed as ‘normal,’ a volume was assigned based on average 
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values reported in the literature:  300mL for vaginal birth,1 and 600mL for Cesarean 
delivery.2   Estimated blood loss was not noted for 23 patients, which were excluded from 
analysis of blood loss.  In case of autologous blood transfusion, 1 unit was assumed to be 
~220mL to calculate units of autologous blood when volume was reported in mL. 
Tobacco use was analyzed by any previous smoking (yes/no) and smoking during accreta 
pregnancy (yes/no).  Availability of data on quantity of tobacco use was insufficient to 
stratify by intensity of use.  Second-hand smoke exposure was not counted as smoking 
exposure.  Medication use and presence of co-morbidities were recorded primarily as a 
proxy for maternal health status.   
For the study, Daniel Bercik performed chart review on 20% of the cases.  Regression 
analysis was performed by Jessica Illuzzi, MD, MS.   
Demographic characteristics, including age, gravidity, parity, race, obstetric history, and 
maternal and perinatal outcomes of mothers with and without previous exposure to 
uterine surgery were compared.   Rates of placenta accreta were calculated annually as 
the number of cases of placenta accreta per 1,000 births, and stratified by focal and non-
focal accreta cases.  Because several accreta pregnancies ended in fetal demise, rates 
were calculated based on data for all births, rather than live births.  Patient categorical 
characteristics were compared using chi-square analysis, except where small number of 
observations necessitated use of Fisher’s exact test.  Continuous variables (e.g. estimated 
blood loss) were analyzed using t-test for focal/non-focal and ANOVA for comparison of 
                                                     
1 Average estimated blood loss (EBL) for vaginal delivery:  287mL, based on findings of 2 studies cited in 
Begley et al 2011, and consistent with other published estimates.(55)  
2 Average EBL for cesarean delivery: 592 +/- 222mL as estimated by obstetricians, in audit of 126 patients 
delivered by cesarean.(56) 
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accreta vera, increta and percreta.  Logistic regression was done to analyze the primary 
outcome of rate of placenta accreta by primary exposure variable of indication for 
cesarean delivery (e.g. objective versus subjective), using time period as the predictive 
variable.  Indications for index uterine surgery were analyzed by logistic regression and 
cumulative annualized relative risk increase (e.g. odds ratio compounded annually over 
the duration of the study period; shows the increase in risk for a patient over the duration 




Patient characteristics   
Comparison between focal and non-focal accreta 
Characteristics of patients with focal and non-focal accreta as well as among those with 
placenta accreta, increta and percreta are compared in Table 1.  Comparing the 100 
patients with non-focal accreta with the 122 cases of focal accreta, there was a significant 
difference in age and gravidity;there were no significant differences in race/ethnicity, 
parity average number of previous cesearean deliveries, and rate of concurrent placenta 
previa.(Table 1)  Grand multiparous women (with ≥ 5 previous births of > 20 weeks 
gestation) made up 3% of cases. (Data not shown)  Overall rate of co-morbidities appear 
to be higher among focal accreta versus no-focal accreta (p=0.04), including 
hysterectomy  ICU admission, rate of transfusion, estimated blood loss, units of red blood 
cells transfused, and duration of hospital stay after delivery.  There was one woman with 
increta who did not undergo hysterectomy.  She was a 37-year old G6P1132 who had a 
previous histologically-confirmed placenta accreta vera in her third pregnancy, which 
was followed by myometrial resection and repair of the area of the accreta; at the time of 
the increta pregnancy, she had had a total of three previous cesarean deliveries, one 
previous curettage, and two previous myomectomies.  In the increta pregnancy, she had 
1L of blood loss, and underwent wedge resection of placenta and adjacent large uterine 




Age 32.1 {6.3} 33.9 {5.2} 0.023 33.3 {4.7} 36.2 {4.3} 33.1 {7.5} 0.060
Race 0.107 0.383
Black 29 (23) 14 (14) 10 (16) 2 (9) 2 (14)
Hispanic 15 (12) 10 (10) 5 (8) 3 (13) 2 (14)
White 69 (57) 72 (72) 46 (73) 18 (78) 8 (57)
Other 
B
9 (7) 4 (4) 2 (3) 0 (0) 2 (14)
Smoking 
Ever 25 (20) 14 (14) 0.206 7 (11) 3 (13) 4 (29) 0.260
Current 18 (15) 7 (7) 0.069 1 (2) 2 (9) 4 (29) 0.003
Obstetrical history
Gravidity 3 (2‐4) 3 (2‐5) 0.005 3 (2‐4) 4 (2‐5) 5.5 (4‐7) 0.001
Parity 1 (0‐1) 1 (0‐2) 0.0003 1 (0‐2) 1 (1‐2) 2 (1‐3) 0.316
Uterine surgery
Cesarean deliveries (#) 0.27 {0.55} 1.05 {1.13} <0.0001 0.78 {1.02} 1.22 {1.0} 2.00 {1.3} 0.001
Curettage (#) 0.75 {1.12} 0.93 (1.91} 0.397 0.7 {1.06} 0.78 {1.0} 2.21 {4.34} 0.024
Other uterine surgery (#) 
C
0.1 {0.42} 0.25 {0.6} 0.042 0.26 {0.66} 0.32 {0.57} 0.07 {0.27} 0.461
Multiple gestation 22 (18) 6 (6) 0.007 5 (8) 0 (0) 1 (7) 0.459
IVF (during accreta pregnancy) 13 (10) 10 (10) 0.873 7 (11) 2 (9) 1 (7) 1.000
Placenta previa 13 (10) 45 (45) <0.0001 22 (35) 13 (57) 10 (71) 0.021
Comorbidities 
D
88 (72) 59 (59) 0.040 34 (59) 14 (61) 11 (79) 0.234
Preeclampsia or hypertension 
E
36 (30) 17 (17) 0.030 8 (17) 5 (22) 4 (29) 0.241
DM 21 (17) 14 (14) 0.513 7 (14) 2 (9) 5 (36) 0.077
Obesity 9 (7) 7 (7) 0.914 4 (7) 2 (9) 1 (7) 0.859
Medications 40 (33) 25 (25) 0.205 11 (25) 8 (35) 6 (43) 0.065
Age >= 35 years 49 (40) 44 (44) 0.564 24 (44) 16 (70) 4 (29) 0.015
Substance abuse 7 (6) 6 (6) 0.934 2 (6) 2 (9) 2 (14) 0.105
Asthma 12 (10) 9 (9) 0.832 3 (9) 4 (17) 2 (14) 0.108
Asherman's syndrome 2 (2) 4 (4) 0.413 4 (4) 0 (0) 0 (0) 0.607
Outcomes
Maternal
Hysterectomy 7 (6) 68 (68) <0.0001 34 (54) 22 (96) 14 (100) 0.0004
Multiple cases of accreta 0 (0) 3 (3.0) 0.090 2 (3) 1 (4) 0 (0) 1.000
ICU admission 7 (6) 42 (42) <0.0001 19 (30) 12 (52) 11 (79) 0.002
Transfused 18 (15) 61 (61) <0.0001 29 (46) 19 (83) 13 (93) 0.0003
Estimated blood loss (L) 0.9 {0.9} 3.6 {5.2} <0.0001 2.5 {4.3} 4.6 {6.3} 6.9 {5.4} 0.007
Units of pRBCs transfused 4.1 {3.0} 10.2 {7.4} <0.0001 8.9 {6.4} 9.7 {8.6} 13.9 {6.8} 0.125
Duration of hospital stay after 
delivery (days) 4.6 {2.2} 7.0 {7.4} 0.002 6.1 {5.2} 6.7 {3.6} 11.9 {15.3} 0.028
Perinatal
Gestational age 36.7 {5.0} 34.8 {7.2} 0.006 34.8 {5.9} 33.1 {6.0} 27.8 {11.0} 0.004
Gender
F 70 (59.8) 42 (47.2) 0.071 27 (47.4) 8 (36.4) 7 (70.) 0.210
Baby to NICU 53 (43.4) 36 (36.) 0.260 21 (33.3) 11 (47.8) 4 (28.6) 0.382
Intrauterine fetal demise 2 (1.6) 4 (4.0) 0.413 4 (6.4) 0 (0) 0 (0) 0.152
Baby weight (g) 2624  {925} 2641  {752} 0.899 2866  {617} 2406  {617} 2103  {965} 0.008
C






















Data presented as  n(%) for discrete variables, mean {SD} for continuous  variables, median (inter‐quarti le range) for gravidity and parity.    Chi‐square 
test  used except where n was too small; Fisher's  Exact test was  then used instead.
 
Table 1.  Patient characteristics by type of placenta accreta. 
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Comparison between accreta vera, increta and percreta 
Between types of accreta, there was no significant difference in average age or parity at 
accreta delivery.  There was a significant difference among rate of smoking during the 
accreta pregnancy, gravidity, number of previous cesarean deliveries, and placenta 
previa.  Maternal outcomes were significantly more severe among percreta cases in 
comparison with accreta vera cases in regard to: hysterectomy (92.9% versus 54%; p = 
0.0004); ICU admission (78.6% versus 30.2%; p = 0.002); transfusion (92.9% versus 
46.0%; p = 0.0003); estimated blood loss (6.94 L versus 2.47 L; p = 0.007) and duration 
of hospital stay after delivery (11.9 days versus 6.1 days; p = 0.028).  Outcome among 
neonates also differed significantly between types of accreta.   
Description of accreta trends, with focal accreta 
included 
From July 1996 to December 2011, a total of 72,845 births occurred at Yale-New Haven 
Hospital (including still births).  During that time, there were a total of 222 patients with 
placenta accreta diagnosed by histopathology, which is a rate of 3.05 cases per 1,000 
births.(Table 2)  This total includes 122 cases of focal placenta accreta (1.67 per 1,000 
births), 63 cases of placenta accreta vera (0.86 per 1,000 births), 23 cases of placenta 
increta (0.32 per 1,000 births), and 14 cases of placenta percreta (0.19 per 1,000 births).  
To reduce the influence of annual variation, analysis was done by 3-year periods, with the 








E 17,244 3 (.17) 17 (.99) 13 (.75) 3 (.17) 1 (.06) 20 (1.16)
2000‐2002 14,164 17 (1.2) 20 (1.41) 17 (1.2) 2 (.14) 1 (.07) 37 (2.61)
2003‐2005 14,353 33 (2.3) 19 (1.32) 10 (.7) 7 (.49) 2 (.14) 52 (3.62)
2006‐2008 13,864 62 (4.47) 21 (1.51) 15 (1.08) 3 (.22) 3 (.22) 83 (5.99)
2009‐2011 13,220 7 (.53) 23 (1.74) 8 (.61) 8 (.61) 7 (.53) 30 (2.27)















C Accreta vera Increta Percreta All accreta 
D
 
Table 2.  Rates of histologically-diagnosed placenta accreta by type 
Over this time period, the rate of placenta accreta including all cases varied considerably, 
from a nadir of 1.16 in per 1,000 births in 1996-1999 to a peak of 5.99 per 1,000 births in 
2006-2008, with a subsequent sharp decline to 2.27 per 1,000 births in 2009-2011. (Fig.4)   
 
Fig. 4.  Rate of all cases of placenta accreta, per 1,000 births.  Error bars reflect standard 
error of the mean. 
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It would be surprising for the rate of placenta accreta to have a precipitous drop to less 
than half of its previous rate from one 3-year period to the next.  The potential influences 
on this trend are more apparent when the cases are divided by type of accreta: a similar 
pattern is noted in cases of focal placenta accreta: rising from 0.17 per 1000 births in 
1996-1999 to 4.47 per 1,000 births in 2006-2008, followed by a decline to a rate of 0.53 
per 1,000 births in 2009-2011. (Fig. 5)   
 
Fig. 5.  Rate of focal placenta accreta, per 1,000 births.  Error bars represent standard 
error of the mean. 
 
One possible contributor to this trend is suggested by the pattern of diagnosis of focal 
placenta accreta by two particular pathologists: among 18 pathologists who diagnosed 
accreta over the study period, 84% of cases were diagnosed by two pediatric pathologists 
with expertise in the placenta, with a rise in diagnosed focal placenta accreta cases of two 
to three-fold between 2005-2009.  The possible influence of interpathologist variability 
on diagnosis rates is further underscored by the fact that the decline in rate of focal 
accreta diagnosis occurred at the time of their departure from Yale-New Haven Hospital 
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to other institutions.  The decline in rate of focal accreta diagnosis roughly corresponds to 
the timing of their two departures in 2008 and 2009, as indicated  below on the graph of 
focal accreta diagnosis by year.(Fig. 6)  Both of the pathologists had been present prior to 
this increase, and attribute it to an increase in emphasis on diagnosis of focal accreta in 
the literature and pathology conferences. (Personal communication with Miguel Reyes 
Mugica MD and Brian West MD, March 7, 2012).  The diagnosis pattern at our 
institution suggests that there are varying thresholds for the diagnosis of focal accreta 
among some pathologists.  Studies have shown that pathologists without specialization in 
placental pathology have a high rate of underdiagnosis.(61)   
 
Fig. 6.  Rate of focal placenta accreta by year.  Arrowheads depict the timing of departure 
of the two pathologists responsible for 84% of diagnoses of focal placenta accreta across the 
study time period.  Pathologist 1 departed in mid-2007, and pathologist 2 departed in late 
2008. 
 
The presence of this correlation suggests that the sensitivity of diagnosis for focal accreta 
at Yale-New Haven Hospital may have fluctuated over time..  Although there are likely 
other influences also underpinning the fluctuations in rate of focal accreta over the study 
period, we felt this fluctuation warranted separation of data for focal placenta accreta 
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from data for accreta vera, increta and percreta.   Thus, the focal accreta cases were 
analyzed separately and excluded from analysis of trends in rate of incidence and 
exposure to previous uterine surgery.   
Exposure to uterine surgery among non-focal accreta 
cases 
Among patients with non-focal accreta, there was a significant difference between rate of 
exposure to index uterine surgery (p = 0.039); see Table 3.  Among women with accreta 
vera, 42.9% had cesarean delivery as their index exposure, 20.6% had D&C, 12.7% had 
other uterine surgery (including myomectomy, septum resection, lysis of adhesions, 
endometrial ablation and polypectomy), and 23.8% had no previous uterine surgery 
exposure.  Index surgeries among women with increta were cesarean delivery in 65.2% 
of women, D&C among 13%, other uterine surgery among 17.4% and no uterine surgery 
among 4.4%.  Among women with percreta, index surgery was cesarean delivery in 
85.7%, D&C in 7.1%, other uterine surgery in 7.1%; there were no women with percreta 
who did not have a previous uterine surgery exposure.  Specific previous uterine surgery 
varied significantly by type of non-focal accreta (p = 0.042).  Sixty-four percent of 
women with percreta cases had been exposed to more than one type of uterine surgery 
(e.g. had a history of cesarean delivery, D&C and/or other uterine surgery), in contrast to 
47.8% of women with increta and 22.2% of women with accreta vera (p = 0.042).  On 
average, women with accreta vera had 1.73 previous uterine surgeries (of any type; SD 
1.53); women with increta had an average of 2.0 previous uterine surgeries (SD 1.4), and 






Cesarean delivery 27 (43) 15 (65) 12 (86)
D&C 13 (21) 3 (13) 1 (7)
Other 
A
8 (13) 4 (17) 1 (7)
None 15 (24) 1 (4) 0 (0)
0.042
Cesarean delivery only 17 (27) 7 (30) 3 (21)
Curettage only 13 (21) 3 (13) 2 (14)
Other uterine surgery only 15 (24) 1 (4) 0 (0)
>1 type of uterine surgery 
A,B
14 (22) 11 (48) 9 (64)
None 15 (24) 1 (4) 0 (0)
Total number of previous 












Table 3.  Patient characteristics: exposure to uterine surgery among non-focal accreta cases. 
 
Trend in non-focal accreta rate 
The overall rate of non-focal placenta accreta at Yale-New Haven Hospital between July 
1996 and December 2011 was 1.37 per 1,000 births.(Table 2)  The rate of all non-focal 
cases increased from 0.99 per 1,000 births to 1.74 per 1,000 births, with an average 





















Focal 0.17 1.20 2.30 4.47 0.53 31.6% (16.1 ‐ 49.2%) 3.95 (2.11 ‐ 7.4) <.0001
Non‐focal accreta C 0.99 1.41 1.32 1.51 1.74 12.4% (‐1.6 ‐ 28.5%) 1.79 (0.92 ‐ 3.5) 0.0854
Accreta vera 0.75 1.20 0.70 1.08 0.61 ‐3.2% (‐18.1 ‐ 14.4%) 0.85 (0.37 ‐ 2.0) 0.7046
Increta 0.17 0.14 0.49 0.22 0.61 33.0% (‐0.3 ‐ 78.3%) 4.16 (0.99 ‐ 18.0) 0.0526
Percreta 0.06 0.07 0.14 0.22 0.53 81.9% (17.3 ‐ 182%) 19.9 (2.22 ‐ 179) 0.0075










Table 4.  Change in rate of non-focal placenta accreta over time, per 1,000 births  
    
 
Fig. 7.  Rate of non-focal accreta, per 1,000 births.  Error bars represent standard 
error of the mean. 
 
The rate of placenta accreta vera did not change significantly, with a slight decrease of -
3.2% per 3-year period (95% CI -18.1% – 14.4%), whereas the rate of placenta increta 
increased from 0.17 to 0.61 per 1,000 births, or 33.0% per 3-year period (95% CI -0.3% – 
78.3%).(Fig. 8)  The cumulative risk of placenta accreta vera over this time period was 
0.85 (95% CI 0.37 – 2.0); for increta, it was 4.16 (95% CI 0.99 – 18.0).  The rate of 
41 
 
placenta percreta increased from 0.06 to 0.53 per 1,000 births, or 81.9% per 3-year period 
(95% CI 17.3% – 182%), for a cumulative risk of 2.75 (95% CI 1.75 – 4.3) over the study 
period.   
 
Fig. 8.  Rate of non-focal placenta accreta by type, per 1,000 births.  Error bars 
represent standard error of the mean.  
 
Association between exposure to index uterine surgery 
and risk of non-focal accreta 
Among women with non-focal accreta, index exposure to uterine surgery was cesarean 
delivery for 54 (54%) patients, dilation & curettage for 17 (17%) patients, and other 
uterine surgery for 13 (13%) patients.(Table 5)  Other uterine surgery includes 
myomectomy, septum resection, lysis of uterine adhesions, endometrial ablation and 
polypectomy.  There were 16 patients for whom there was no known exposure to uterine 
surgery.  This analysis was not completed for the cases of focal accreta, due to the 






1996‐1999 B 17 (0.99) 7 (0.41) 2 (0.12) 4 (0.23) 4 (0.23)
2000‐2002 20 (1.41) 8 (0.56) 1 (0.07) 6 (0.42) 5 (0.35)
2003‐2005 19 (1.32) 14 (0.98) 1 (0.07) 2 (0.14) 2 (0.14)
2006‐2008 21 (1.51) 12 (0.87) 1 (0.07) 3 (0.22) 5 (0.36)
2009‐2011 23 (1.74) 13 (0.98) 8 (0.61) 2 (0.15) 0 (0.00)














Table 5.  Non-focal accreta by index exposure to uterine surgery: n (rate per 1,000 
births) 
 
Over the study period, the rate of placenta accreta with cesarean delivery as index uterine 
surgery among all births increased from 0.41 per 1,000 births to 0.65 per 1,000 births; the 
proportion of women with placenta accreta and D&C as index exposure decreased from 
0.23 per 1,000 births to 0.15 per 1,000 births.(Table 5)  Rate of accreta and other uterine 
surgery (OUS) as index exposure changed over time from 0.12 per 1,000 births in 1996-
1999 to 0.07 per 1,000 births in 2000-2008, to 0.61 per 1,000 births in 2009-2011.  Rate 
of non-focal placenta accreta and previous uterine surgery exposure declined from 0.23 
per 1,000 births to 0 per 1,000 births. 
Among women with non-focal placenta accreta, index uterine surgery exposure was 
cesarean delivery for 54 patients; 27 (50%) of these patients underwent surgery for a 
subjective indication (Table 6, Fig. 9).  Nineteen (35%) of these patients had an objective 
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indication for primary cesarean delivery.  Subjective indications included non-reassuring 
fetal heart tracing, labor arrest disorder, suspected macrosomia and elective per maternal 
request in absence of medical indication.  Another 5 (9%) of patients had an unknown 
indication for primary cesarean, and 3 (6%) of patients had preeclampsia listed as the 




G 7 (0.41) 5 (0.29) 1 (0.06) 1 (0.06) 0 (0.)
2000‐2002 8 (0.56) 3 (0.21) 4 (0.28) 0 (0.) 1 (0.07)
2003‐2005 14 (0.98) 7 (0.49) 5 (0.35) 2 (0.14) 0 (0.)
2006‐2008 12 (0.87) 7 (0.5) 4 (0.29) 0 (0.) 1 (0.07)
2009‐2011 13 (0.98) 5 (0.38) 5 (0.38) 2 (0.15) 1 (0.08)






























Table 6.  Cases of non-focal accreta with cesarean section as index uterine surgery 








Fig. 9.  Rate of accreta among women with cesarean section as index uterine surgery 
exposure, by indication for cesarean. 
 
The data can also be considered based on rate of accreta associated with cumulative 
exposure to uterine surgery (e.g. all uterine surgeries prior to accreta pregnancy) either 
total number of exposures (with all exposures taken as equal), or by type of exposure 
(e.g. cesarean only, uterine surgery & curettage, etc).  The overview of this data is 
depicted in Fig. 10A-B.  Based on total number, 22% had one known uterine surgery; 
26% of cases had 2 previous uterine surgeries, 18% had 3 and 18% had 4 or greater.  Of 
course, 16% of women still had no prior uterine surgery exposure.  Based on type of 
uterine surgery exposure (but not taking into account frequency), for 18% of women, 
curettage was their only known surgical exposure; for 27% of women it was cesarean 
delivery alone (1 or more); 5% of women had another uterine surgery as their only 
surgical exposure.  Twenty-two percent of patients had at least one of each cesarean and 
curettage; 5% of patients had all three types of uterine surgery exposure. 
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Fig. 10A.     Fig. 10B. 
 
Fig. 10A-B.  Cumulative exposure to previous uterine surgery.  A.  By total number 
of previous uterine surgeries, including cesarean section, curettage and other 
uterine surgeries. B. By types of uterine surgery.  
 
Among the four categories of exposure to previous uterine surgery, there was a 
significant increase over the study period in the likelihood of cesarean delivery and other 
uterine surgery as types of index exposure to uterine surgery among women with non-
focal placenta accreta.(Table 7)  The rate of cesarean delivery as the index uterine 
surgery increased by 21.9% per 3-year period (95% CI 1.4% - 46.6%).  This translated to 
a cumulative risk of 2.69 (95% CI 1.07 – 6.8), meaning that among all births over the 
duration of the study, women were 2.69 times more likely to have an accreta in the 
setting of a prior index cesarean delivery at the end of the study period (2009-2011) 
compared to the beginning (1996-1999).  For other uterine surgery, the average increase 
over each 3-year interval was 71.1% per 3-year period (95% CI 10.4% - 165%), with a 
cumulative risk of 14.66 (95% CI 1.64 - 131).  The rates of curettage and for no previous 
exposure to uterine surgery did not change significantly.  There was no significant change 
in the rate of non-focal placenta accreta associated with any of the indications for 
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cesarean delivery: subjective, objective or unknown, though the rates of each increased 
slightly.  Subjective indication increased slightly, at 13.2% per 3-year period (95% CI -
12.4% - 46.4%), objective indication increased by 30.4% per 3-year period (95% CI -
5.1% - 79.1%).  Preeclampsia was included as a separate category; although it is not an 
absolute indication for cesarean delivery, it is often noted as such with no other data 




















Cesarean delivery 0.41 0.56 0.98 0.87 0.98 21.9% (1.4 ‐ 46.6%) 2.69 (1.07 ‐ 6.8) 0.0352
Curettage 0.23 0.42 0.14 0.22 0.15 ‐12.8% (‐37.0 ‐ 20.8%) 0.50 (0.10 ‐ 2.6) 0.4110
Other uterine surgery C 0.12 0.07 0.07 0.07 0.61 71.1% (10.4 ‐ 165%) 14.66 (1.64 ‐ 131) 0.0163
No uterine surgery 0.23 0.35 0.14 0.36 0.00 ‐16.4% (‐40.5 ‐ 17.3%) 0.41  0.07 ‐ 2.2) 0.2993
Indications for cesarean delivery
Subjective D 0.29 0.21 0.49 0.50 0.38 13.2% (‐12.4 ‐ 46.4%) 1.86 (0.52 ‐ 6.7) 0.3433
Objective E 0.06 0.28 0.35 0.29 0.38 30.4% (‐5.1 ‐ 79.1%) 3.77 (0.77 ‐ 18.4) 0.1014
Preeclampsia F 0.00 0.07 0.00 0.07 0.08 49.0% (‐36.0 ‐ 247%) 7.34 (0.11 ‐ 501) 0.3549















Table 7.  Rate of non-focal placenta accreta associated with index uterine surgery and 
indication for index cesarean delivery. 
 
 
Characteristics of women with no prior uterine surgery 
Of the 16 women with placenta accreta who had no known previous uterine surgery 
exposure, there were no smokers or women with history of preeclampsia.  The average 
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gravidity was 2.0 and parity was 0.8.  In nine of these women (56%), a potential risk 
factor could be identified: three women had a documented abortion, but method was 
undocumented; four patients were of advanced maternal age (age ≥ 35 years); one patient 
had a history of Hodgkin's lymphoma with radiation therapy; one patient had transfusion-
dependent thrombotic thrombocytopenic purpura, with weekly or biweekly 




Analysis of pathology-confirmed placenta accreta from a major academic medical center 
reveals an increasing rate of non-focal placenta accreta over the past 15 years (OR 1.12, 
95% CI 0.98 - 1.29).  The increasing rate is consistent with other literature, and with 
statistical modeling that predicts an ongoing increase in rate of placenta accreta in 
parallel with the trend of the cesarean section rate.  This change is driven by an increase 
in increta (OR 1.33, 95% CI 0.98 – 1.17) and particularly percreta (OR 1.82 95% CI 1.17 
– 2.82).  A woman with placenta accreta was 19.9 times more likely to have percreta if 
she presented in 2009-2011 compared with a woman in 1996-1999.   
With the increased rate of the more invasive degrees of accreta, there is also an increase 
in severity of clinical presentation and outcomes.  Women with percreta had significantly 
more several clinical outcomes as gauged by rate of hysterectomy, ICU admission, blood 
transfusion, estimated blood loss and duration of hospital stay compared with women 
with placenta accreta.  Through the course of this study, there has been an increasing 
awareness reflected in the literature of the need to optimize management of placenta 
accreta, including through planned early cesarean delivery and use of multi-disciplinary 
teams, to minimize morbidity and mortality.(5,10,50)  Although this study does not 
evaluate management patterns, it is clear that placenta accreta continues to pose a 
challenging clinical management scenario.  In our case series, there was one maternal 
death (1%) among the cases of non-focal placenta accreta in a mutigravida with 
antenatally-diagnosed placenta percreta.  In our study, women with percreta all had three 
or more previous uterine surgery exposures.  It is difficult to quantify the degree of 
endometrial disruption that occurs by type of uterine surgery; however, in light of the rate 
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of rise of the percreta rate, it is worth taking an inclusive view of uterine instrumentation 
in evaluating risk of placenta percreta – particularly including myomectomy, endometrial 
ablation, and other invasive procedures, as well as curettage.  
In this study, there was a significant increase in rate of accreta associated with exposure 
to cesarean delivery as the index uterine surgery.  This is not surprising, as the cesarean 
delivery rate continues to climb.  At Yale-New Haven Hospital, the cesarean rate 
increased from approximately 20 to over 35% between 1996 and 2009, an increase of 
75%.(13)  There was a significant change in the rate of primary cesarean exposure for 
subjective indications over this time period; however, the rate of placenta accreta with a 
prior index cesarean for subjective indications did not increase significantly.  However, if 
more than 60% of the increase in the primary cesarean delivery rate is due to more 
subjective indications suggests, it suggests that, theoretically, with the benefit of 
improved tools to guide acute obstetric management, we can safely reduce the cesarean 
rate.   
Ways to reduce the cesarean rate are under debate.  Thorough patient counseling of the 
risks and benefits of primary cesarean and also of trial of labor after cesarean – 
particularly for women who desire three or more children – is crucial.  One author also 
suggests setting reimbursement levels for successful VBAC to the same level as that of 
elective repeat cesarean deliveries, to prevent any financial incentive for cesarean.(3)  A 
recent Cochrane review evaluated the effectiveness and safety of non-clinical 
interventions for reducing unnecessary cesarean sections.(63)  Strategies that show 
promise include provider directed efforts, including implementing guidelines with 
mandatory second opinion,(64) mandatory second opinion and peer review feedback at 
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department meetings(65), guideline implementation with support from local opinion 
leaders,(66) and maternal-directed of prenatal education, support programs, computer 
patient decision-aids, and intensive group therapy, though evidence for their effectiveness 
is less strong to date.(63) 
Case identification for cases of placenta accreta was found to be more reliable via 
histopathologic diagnosis compared with ICD-9 code query.  In our study, ICD-9 code 
had a 9% positive predictive value for histopathologic diagnosis of placenta accreta.  Of 
greatest importance, 69.5% of pathology-confirmed accreta cases were falsely negative 
for placenta accreta according to ICD-9 code.  Use of ICD-9 code to identify placenta 
accreta should be avoided in future investigations.  A better strategy would be to use 
histopathologic diagnosis, and also to consider establishment of a placenta accreta case 
registry to enable broader analysis of this relatively rare pathology.    
In addition, there is evidence that the rate of focal placenta accreta has been as high as 
5.20 per 1,000 births, but also that sensitivity of diagnosis has varied considerably 
between pathologists and degrees of awareness of the problem of milder placenta accreta. 
In the case of focal placenta accreta, increase in diagnosis over the middle part of the 
study period likely reflected in part an increase in awareness associated with the 
publication of several studies highlighting focal accreta. (Personal communication with 
Miguel Reyes Mugica MD and Brian West MD, March 7, 2012)  Across all types of 
accreta, improved diagnostic capabilities through antenatal ultrasound may account for 
part of the increase in antenatal diagnosis over the past several decades.  However, 
standards for histopathologic diagnosis of accreta vera, increta and percreta have not 
changed significantly, and it is less likely that the increase in incidence of pathology-
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confirmed accreta is attributable to improved clinician awareness or increased diagnostic 
testing.  
Placenta accreta is usually considered to be a clinically candid disease, with striking 
presentation and outcomes; our true understanding is hindered by a surprising diagnostic 
gray area.  All agree that a difficult placental delivery and/or massive hemorrhage with 
placental or uterine histopathological evidence of basal plate myometrial fibers 
constitutes placenta accreta.  However, the appropriate characterization of both incidental 
pathological diagnosis of accreta without typical clinical signs and clinically severe cases 
that are diagnosed by solely clinical findings (e.g. are just diagnosed clinically), remain a 
source of relatively unfocused debate.  This is particularly concerning, in view of the 
evidence that diagnosis of pathology in placenta specimens has considerable interoperator 
variability.(55)   
Though generally agreed to be increasing, there remains significant variation among 
published estimates of the rate of placenta accreta.  In addition to differences between 
populations, this is due to variation in diagnostic criteria employed – in particular, 
clinical versus histopathologic from hysterectomy specimen versus histopathologic from 
placental specimen.  Both in relation to pathologic diagnosis and in general, a standard 
set of criteria for diagnosis of placenta accreta would benefit our efforts to better 
understand the patterns of incidence and permit improved comparison between studies.  
One of the strengths of this paper was inclusion of all pathology-defined cases identified 
in both hysterectomy and placental specimens, unlike most previous studies, which more 
often limit pathology specimens to hysterectomy. Although use of stringent inclusion 
criteria is important, including only cases in which hysterectomy was performed biases 
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our understanding of placenta accreta by failing to consider potentially less clinically 
severe, but nevertheless relevant cases of placenta, including cases in which 
hysterectomy was a near-miss.  In this study, hysterectomy rate averaged 68% across all 
non-focal accreta, and exceeded 96% for both placenta increta and percreta.  However, 
instead of restricting to hysterectomy cases, it is arguably more important to include 
criteria that will capture the near-miss cases where conservative management may have 
succeeded, in order to gain insight into optimization of management and to have a more 
accurate estimate of the extent of this disease.  This paper thus may contribute to the 
working definition of placenta accreta and the development of standard diagnostic 
criteria.   
There are a number of limitations to this study.  First, by including only pathology-
confirmed cases of placenta accreta, we may have excluded cases that were clinically 
significant but in which the placenta was not submitted for pathological examination, or 
in which the specimen was insufficient to make a diagnosis, and thus possibly 
underestimated the rate of placenta accreta.  This possible underestimate is increased by 
excluding cases of focal placenta accreta.  Nevertheless, comparing the rates with those 
found by other recent studies using combined clinical and histopathological diagnosis, 
our findings are consistent.  Moreover, you would expect broader inclusion criteria to 
result in greater sensitivity of diagnosis and thus higher estimated rates. 
The small sample size was a limitation of this study.  The sample size was further 
reduced by our decision to restrict analysis to non-focal accreta; however, the variation in 
sensitivity of diagnosis of focal accreta would have introduced unacceptable uncertainty 
into our analysis.  In the future, extension of a larger project to draw from a broader 
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population, including non-tertiary care facilities, would be an improvement.  By 
stratification of accreta into degree of invasiveness (accreta vera, increta, percreta), it 
enabled comparison within our case series, to better define the trends between these 
groups.  This is particularly relevant, given that our study also found a higher rate of 
antenatal diagnosis among cases of placenta percreta compared with increta and 
accreta(data not shown), which implies better ability of the clinical team to prepare to 
optimize delivery.  Despite the small size of our case series, the ability to stratify by type 
of accreta and review trends in incidence within these strata is provides an important 
insight into patterns of placenta accreta at our institution.  Moreover, our demonstration 
of the variation in the focal accreta rate based on variation in pathological diagnosis is 
relevant for future studies.   
A second potential limitation is our baseline assumptions.  For instance, by assigning a 
standard value for ‘normal’ estimated blood loss (300mL for vaginal birth, 600mL for 
cesarean delivery), we may have distorted the actual pattern of blood loss among accreta 
deliveries. 
Larger studies of placenta accreta are needed.  In a future case-control study, it would be 
interesting to include analysis of degree of anemia (by hemoglobin/hematocrit), and use 
of medications such as nifedipine and other tocolytics, antihypertensives and iron as 
exposures to correlate with the outcome of placenta accreta.  Each of these might 
influence accreta risk by lowering oxygen carrying capacity or blood pressure.  
Randomized controlled trials are necessary.  However, even before that, establishing use 
of accreta tracking systems would be useful to following trends.  For instance, at Yale-
New Haven Hospital, a research RN in the labor & birth department records all deliveries 
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by mode of delivery and indication, and whether delivered by private, university or high-
risk provider, which provides a powerful tool for analysis.  In a future study, it would 
also be useful to seek to compare the rates of antenatal/ultrasound, clinical and 
pathological diagnosis in order to help establish the best diagnostic methods for 
identifying accreta and related types, in order to prevent misclassification of cases and 
better understand etiology and strategies for prevention. 
In conclusion, over the last 15 years, the rate of non-focal accreta has increased, 
paralleled by an increase in proportion of more severe degrees of invasion and more 
severe clinical presentation and outcomes.  As antenatal diagnosis and peripartum 
management improve, secondary prevention will likely become more effective.  Better 
provider preparation and provision of multi-disciplinary peripartum care has been shown 
to improve outcomes, but will not help turn the tide of this growing problem.  It is 
important to seek better understanding of potential modifiable risk factors that may aid in 
primary prevention, including exposure to uterine surgery, and to balance the short-term 
indications that support uterine surgery with the desire to prevent women from 
unnecessarily crossing that gateway to increased risk of complications.   Central to this 
effort will be patient education, including strategic discussion about number of desired 
pregnancies and long-term risks.  Rates of myomectomy and other uterine procedures 
have also increased over time.  A clearer picture of the rates of placenta accreta 
associated with various uterine surgeries and their contributions to current increases in 
placenta accreta is essential, so we can seek to divert childbearing women currently 
headed down the potentially risky path of multiple uterine surgeries, and joining the ranks 
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